Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects

被引：0
|
作者：
Katsuyuki Murase
Lucy Lee
Jiyuan Ma
Rosemary Barrett
Martin Thoolen
机构：
[1] PTC Therapeutics,
[2] Inc.,undefined
来源：
European Journal of Clinical Pharmacology | 2022年 / 78卷
关键词：
Vatiquinone; Drug-drug interactions; Pharmacokinetics; CYP inhibition; Healthy volunteers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1823 / 1831
页数：8
相关论文
共 50 条
  • [41] CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects
    Yin, OQP
    Tomlinson, B
    Chow, MSS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) : 370 - 377
  • [42] Impacts of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide in Chinese subjects
    Zhang, Yifan
    Chen, Xiaoyan
    Lin, Nan
    Zhong, Dafang
    Si, Dayong
    Gu, Yingjie
    Zhou, Hui
    DRUG METABOLISM REVIEWS, 2006, 38 : 161 - 162
  • [43] Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1
    Powers, Jennifer L.
    Buys, Saundra S.
    Fletcher, Deborah
    Melis, Roberta
    Johnson-Davis, Kamisha L.
    Lyon, Elaine
    Malmberg, Elisabeth M.
    McMillin, Gwendolyn A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (12): : 1570 - 1581
  • [44] Impact of CYP2C9 and CYP2C19 polymorphisms in drug-induced idiosyncratic liver injury (DILI)
    Pachkoria, K.
    Lucena, M. I.
    Ruiz-Cabello, F.
    Crespo, E.
    Hidalgo, R.
    Cabello, M. R.
    López-Torres, E.
    Cueto, R.
    Andrade, R. J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 : 50 - 50
  • [45] CYP2D6, CYP2C19 AND CYP2C9 GENOTYPING IN A SWEDISH CLINICAL SETTING
    Scordo, M. G.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E9 - E9
  • [46] Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects
    Guevara, Natalia
    Maldonado, Cecilia
    Uria, Manuel
    Gonzalez, Raquel
    Ibarra, Manuel
    Alvariza, Silvana
    Carozzi, Antonella
    Azambuja, Carlos
    Fagiolino, Pietro
    Vazquez, Marta
    PHARMACEUTICALS, 2017, 10 (03)
  • [47] Drug interaction between omeprazole and clarithromycin with relation to CYP2C19 status.
    Ohashi, K
    Furuta, T
    Kobayashi, K
    Kosuge, K
    Kaneko, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 128 - 128
  • [48] The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study
    Yao, Yuan
    Han, Wei-Wei
    Zhou, Yi-Han
    Li, Ze-Sheng
    Li, Qiang
    Chen, Xiao-Yan
    Zhong, Da-Fang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (02) : 854 - 861
  • [49] Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib
    De Zwart, Loeckie
    Snoeys, Jan
    Jacobs, Frank
    Li, Lilian Y.
    Poggesi, Italo
    Verboven, Peter
    Goris, Ivo
    Scheers, Ellen
    Wynant, Inneke
    Monshouwer, Mario
    Mamidi, Rao N. V. S.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (09): : 1107 - 1118
  • [50] A Pharmacokinetic Model of Drug-Drug Interaction between Clopidogrel and Omeprazole at CYP 2C19 in Humans
    Tangamornsuksan, Wimonchat
    Thiansupornpong, Pongpak
    Morasuk, Thirawut
    Lohitnavy, Ornrat
    Lohitnavy, Manupat
    2017 39TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), 2017, : 2704 - 2707
12345